title: IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes.
abstract: IL-10 markedly reduces nuclear factor (NF)-kappa B/Rel nuclear activity induced in PBMC by stimulation with the anti-CD3 mAb OKT3. The inhibition is exerted specifically on the NF-kappa B/Rel activation induced by mAb OKT3, and not that produced by PMA. As judged by supershifting the DNA-protein complexes with Abs recognizing specific components of the NF-kappa B/Rel protein family, the p50/p65 (Rel A) heterodimeric form of NF-kappa B is primarily affected. The maximal effect is observed at the IL-10 concentration of 20 U/ml. IL-10 inhibitory activity is exerted on T lymphocytes and is mediated by monocytes. Indeed, monocytes pretreated with IL-10 are able so inhibit NF-kappa B nuclear activity in purified T lymphocytes stimulated with OKT3. Soluble factors do not appear to be involved in the mechanism of inhibition. On the other hand, the up-regulation of CD80 Ag, found on monocytes obtained from PBMC incubated with OKT3, is not detected after addition of IL-10, and the anti-CD28 mAb CLB-CD28/1 restores the NF-kappa B/Rel nuclear activity in IL-10-inhibited lymphocytes. Therefore, the NF-kappa B/Rel inhibition might be ascribed to a lack of cooperation between accessory cells and T lymphocytes, resulting from down-regulation of a costimulatory molecule, such as CD80, produced by IL-10 on activated monocytes. Our results demonstrate that IL-10 can inhibit the induction of NF-kappa B/Rel nuclear activity in CD3-stimulated T lymphocytes. Since inappropriate activation of kappa B-driven genes has a physiopathologic role in a number of diseases, such as HIV infection, our findings support the possibility of using this cytokine to suppress an undesirable activation of these transcription factors.
authors.affiliation: Department of Biochemistry, Federico II University, Napoli, Italy.
authors.forename: M F
authors.initials: MF
authors.lastname: Romano
authors.forename: A
authors.initials: A
authors.lastname: Lamberti
authors.forename: A
authors.initials: A
authors.lastname: Petrella
authors.forename: R
authors.initials: R
authors.lastname: Bisogni
authors.forename: P F
authors.initials: PF
authors.lastname: Tassone
authors.forename: S
authors.initials: S
authors.lastname: Formisano
authors.forename: S
authors.initials: S
authors.lastname: Venuta
authors.forename: M C
authors.initials: MC
authors.lastname: Turco
mesh_terms: D001483:Base Sequence; D017252:CD3 Complex / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D015536:Down-Regulation / Q000276:immunology; D006801:Humans; D016753:Interleukin-10 / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008969:Molecular Sequence Data; D009000:Monocytes / Q000276:immunology; D016853:Muromonab-CD3 / Q000494:pharmacology; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D017252:CD3 Complex; D016853:Muromonab-CD3; D016328:NF-kappa B; D016753:Interleukin-10; D013755:Tetradecanoylphorbol Acetate